• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Management

More Evidence Suggesting Convalescent Plasma Therapy May Be Effective in Patients with Severe COVID-19

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Duan et al. (PNAS, 2020) assessed the effectiveness of convalescent plasma in treating severe COVID-19 cases

METHODS:

  • Prospective study (January 23, 2020, to February 19, 2020)
    • 3 hospital in Wuhan, China
    • There was no control arm | Historic control group of randomly selected, matched individuals were used for comparison | Match based on hospital, age, gender, and severity
  • Participants
    • Patients with severe, confirmed COVID
  • Intervention
    • One dose of 200 mL of convalescent plasma
    • Maximal supportive care and antiviral agents
  • Study design
    • Convalescent plasma came from recently recovered donors with the neutralizing antibody titers above 1:640
    • Patients were monitored for clinical symptoms and laboratory parameters within 3 days after transfusion
    • Primary endpoint: Safety
    • Secondary endpoints: Changes in clinical course

RESULTS:

  • Ten patients received convalescent plasma
    • Underlying chronic disease: 4 patients (cardiovascular and/or cerebrovascular diseases and essential hypertension)
    • Median age: 52.5 years (IQR 45.0 to 59.5 years)
    • Median time from onset of illness to transfusion was 16.5 days
  • Levels of neutralizing antibody were high after transfusion
    • Rapid increase up to 1:640 in 5 cases
    • High level (1:640) maintained in four cases

Clinical Course

  • Clinical symptoms were significantly improved within 1 to 3 days following transfusion
    • Within 3 days oxyhemoglobin saturation increased
    • Lymphocyte counts increased
      • Pre-transfusion: 0.65 × 109/L
      • Post transfusion: 0.76 × 109/L
    • C-reactive protein decreased
      • Pre-transfusion: 55.98 mg/L
      • Post-transfusion: 18.13 mg/L
    • Chest CT findings: Within 7 days radiological examinations showed varying degrees of absorption of lung lesions
  • Viral load
    • Undetectable within 6 after transfusion in 7 patients with previous viremia
  • Side effects: None documented

Historic Control Group

  • 10 matched controls (did not receive transfusion) were selected
  • Baseline characteristics: No significant differences when compared to group receiving transfusion
  • Outcomes: The transfusion group did significantly better than the control (P < 0.001)
    • Transfusion group: 3 cases discharged | 7 cases much improved status and ready for discharge
    • Historic control group: 3 deaths | 6 stabilized | 1 improved

CONCLUSION:

  • The results of this study provide more evidence for the effectiveness of convalescent plasma therapy for patients with severe COVID-19
    • There were no major side effects
    • Symptoms improved in all patients
    • Viral load decreased
  • The authors emphasize that despite encouraging findings, larger controlled trials are needed to fully determine the safety and effectiveness

Learn More – Primary Sources:

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

ARDS, Critical Care and COVID-19: ‘Surviving Sepsis Campaign’ Guidelines and Key Points
Use of Convalescent Plasma in Critically Ill COVID-19 Patients: Results from a Preliminary Study
Washington State’s First COVID-19 Cases: Outcomes and Characteristics of 21 Critically Ill Patients
NEJM Correspondence: Clinical Course of COVID-19 in Children

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site